<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82104">
  <stage>Registered</stage>
  <submitdate>19/06/2007</submitdate>
  <approvaldate>20/06/2007</approvaldate>
  <actrnumber>ACTRN12607000332426</actrnumber>
  <trial_identification>
    <studytitle>Omega-3 fatty acids for ADHD symptoms and learning difficulties in children</studytitle>
    <scientifictitle>Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children</scientifictitle>
    <utrn />
    <trialacronym>N3AD</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Attention deficit hyperactivity disorder, learning difficulties in 7-12 year old children</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This double-blind trial will supplement children with 1g eicosapentaenoic acid (EPA), 1g of docosahexaenoic acid (DHA) or linolenic acid (LA; sunflower oil placebo) in capsule format (4 capsules per day) in a 3 x 3 crossover trial over 12 months. It is expected that 4 months on each oil will provide a sufficient washout from the previous oil.</interventions>
    <comparator>Linolenic acid (LA; sunflower oil placebo)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Conners Parent Rating Scales</outcome>
      <timepoint>Measured at 0, 4, 8 and 12 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cognitive assessments of attention, impulsivity and literacy</outcome>
      <timepoint>Measured at 0, 4, 8 and 12 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Erythrocyte omega-3 fatty acid levels</outcome>
      <timepoint>Measured at 0, 4, 8 and 12 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Phospholipase enzyme (PLA2) activity</outcome>
      <timepoint>Measured at baseline.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Eicosanoid levels</outcome>
      <timepoint>Measured at baseline.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children, ADHD diagnosis, parent-reported learning difficulties, willing to fufil requirements of the study.</inclusivecriteria>
    <inclusiveminage>7</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Cannot be on stimulant medication, cannot have taken omega-3 supplements for up to 3 months, must not have haemophilia.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment will be done by receipt of numbered containers by the manufacturer.</concealment>
    <sequence>Children will be stratified according to age and gender then block randomised in using PEPI computer software.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>All participants and researchers (including the people administering the treatment/s, the people assessing the outcomes, the people analysing the results/data, and data entry) will be blinded to the treatments.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>16/07/2007</anticipatedstartdate>
    <actualstartdate>21/06/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate>6/06/2008</actualenddate>
    <samplesize>120</samplesize>
    <actualsamplesize>90</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Nutritional Physiology Research Centre, University of South Australia</primarysponsorname>
    <primarysponsoraddress>University of South Australia
GPO Box 2471
Adelaide SA 5001
Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian Research Council Linkage grant (APDI)</fundingname>
      <fundingaddress>GPO Box 2702
CANBERRA
ACT 2601
AUSTRALIA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Industry partner Novasel Australia</fundingname>
      <fundingaddress>29 Raffles Crt
Mudgeeraba, QLD 4213</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Australian Technology Network (ATN) Centre for Metabolic Fitness</fundingname>
      <fundingaddress>N/A virtual network</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>South Australian (SA) Health Department (PhD scholarship)</fundingname>
      <fundingaddress>Department of Education and Training
GPO Box 9880
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Queensland University of Technology</sponsorname>
      <sponsoraddress>60 Musk Avenue 
Kelvin Grove Urban Village
Kelvin Grove, Queensland, 4059 </sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The principal aim of this project is to investigate effects of supplementation with the omega-3 (n-3) polyunsaturated fatty acids (PUFA) EPA and DHA on symptoms of attention deficit hyperactivity disorder (ADHD), specifically hyperactivity, impulsivity, inattention and cognitive problems, in 7-12 year old children. We also aim to investigate blood fatty acid profiles before, during and after the intervention. This 12-month controlled intervention trial will be conducted in Adelaide and Brisbane in 2007/08.</summary>
    <trialwebsite />
    <publication>Milte CM, Sinn N*, Buckley JD, Coates AM, Young R, Howe PRC (2011). Polyunsaturated fatty acids, cognition and literacy in children with ADHD with and without learning difficulties. Journal of Child Health Care. 15(4):299-311. 

Milte C, Parletta N*, Buckley JD, Coates AM, Young RM, Howe PRC (2012). Eicosapentaenoic and docosahexaenoic acids, cognition and behavior in children with attention deficit/hyperactivity disorder: A randomised controlled trial. Nutrition, 28(6):670-677.

Milte CM, Parletta N*, Buckley JD, Coates AM, Young RM, Howe PRC (2015). Increased erythrocyte eicosapentaenoic acid and docosahexaenoic acid are associated with improved attention and behaviour in children with ADHD in a 12-month randomised controlled three-way crossover trial. Journal of Attention Disorders. 19(11):954-964</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of South  Australia Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>31/05/2007</ethicapprovaldate>
      <hrec>P045/07</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>QUT</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Natalie Sinn</name>
      <address>Nutritional Physiology Research Centre
University of South Australia
GPO Box 2471
Adelaide SA 5001</address>
      <phone>+61 8 83021757</phone>
      <fax>+61 8 83022178</fax>
      <email>natalie.sinn@unisa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Natalie Sinn</name>
      <address>Nutritional Physiology Research Centre
University of South Australia
GPO Box 2471
Adelaide SA 5001</address>
      <phone>+61 8 83021757</phone>
      <fax>+61 8 83022178</fax>
      <email>natalie.sinn@unisa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Natalie (Sinn) Parletta</name>
      <address>University of South Australia
GPO Box 2471
Adelaide SA 5001
Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Natalie Parletta</name>
      <address>University of South Australia
GPO Box 2471, CEA-08
Adelaide SA 5001</address>
      <phone>+61883021757</phone>
      <fax />
      <email>natalie.parletta@unisa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>